<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02597946</url>
  </required_header>
  <id_info>
    <org_study_id>1200.222</org_study_id>
    <nct_id>NCT02597946</nct_id>
  </id_info>
  <brief_title>Afatinib in NSCLC With HER2 Mutation</brief_title>
  <official_title>A Phase II Study of Afatinib in Patients With Advanced NSCLC Harboring HER2 Mutations, Previously Treated With Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      to investigate effectiveness and safety of afatinib in the advanced NSCLC patients with HER2
      mutations, previously treated with 1 or 2 chemotherapy regimens
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) in part A according to RECIST 1.1</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) in part A</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) in part A</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression(TTP) in part A</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response(DOR) in part A</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>all patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: all enrolled patients will receive afatinib monotherapy. Part B: all eligible patients will receive afatinib combined with weekly paclitaxel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>afatinib</intervention_name>
    <arm_group_label>all patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <arm_group_label>all patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients with Histologically or cytologically confirmed diagnosis of stage IIIb/IV
             NSCLC (AJCC 7.0), who had failed one or two systemic chemotherapy regimens, one of
             which must be platinum-based .

          -  Tumor tissue with HER2 mutations as confirmed by AmoyDxÂ® HER2 Mutation Detection Kit

          -  Patients with at least one measurable tumor lesion that can accurately be measured by
             CT scan or MRI according to RECIST 1.1

          -  Age&gt;=18 years

          -  ECOG performance score 0 or 1

          -  Adequate organ function

          -  Recovered from any previous therapy related toxicity to &lt;=Grade 1 at study entry
             (except for stable sensory neuropathy &lt;=Grade 2 and alopecia)

          -  Written informed consents that is consistent with ICH-GCP and local GCP guidelines
             Inclusion criterion for Part B

          -  Adequate organ function, as inclusion criteria No.6

          -  ECOG performance score 0~2

          -  More than 12 weeks clinical benefit (PR, CR, SD) in part A Further inclusion criteria
             apply

        Exclusion criteria:

          -  Prior treatment with EGFR or HER2 targeting small molecules or antibodies.

          -  Any chemo-, or immune anticancer therapy within 4 weeks prior to start of study
             treatment, Hormonal treatment within 2 weeks prior to start of study treatment,
             Radiotherapy within 4 weeks prior to start of treatment, except as follows:

             i.) Palliative radiation to target organs other than chest may be allowed up to 2
             weeks prior to enter, and ii.) Single dose palliative treatment for symptomatic
             metastasis outside above allowance to be discussed with sponsor prior to enrolling.

          -  Major surgery within 4 weeks before starting study treatment or scheduled for surgery
             during the projected course of the study

          -  Known hypersensitivity to afatinib or the excipients of any of the trial drugs

          -  History or presence of clinically relevant cardiovascular abnormalities such as
             uncontrolled hypertension, congestive heart failure NYHA classification of &gt;= 3,
             unstable angina or poorly controlled arrhythmia as determined by the investigator.
             Myocardial infarction within 6 months prior to randomisation.

          -  Any history of or concomitant condition that, in the opinion of the Investigator,
             would compromise the patient's ability to comply with the study or interfere with the
             evaluation of the efficacy and safety of the test drug.

          -  Previous or concomitant malignancies at other sites, except effectively treated
             non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ
             or effectively treated malignancy that has been in remission for more than 3 years and
             is considered to be cured.

          -  Requiring treatment with any of the prohibited concomitant medications

          -  Known pre-existing interstitial lung disease.

          -  Any history or presence of poorly controlled gastrointestinal disorders that could
             affect the absorption of the study drug.

          -  Active hepatitis B infection and/or active hepatitis C infection and/or known HIV
             carrier.

          -  Leptomeningeal carcinomatosis.

          -  Symptomatic brain metastases; To be eligible patients must be asymptomatic from brain
             metastases at least 4 weeks without requirement for steroids or anti-epileptic
             therapy.

          -  Women of child-bearing potential (WOCBP) and men who are able to father a child,
             unwilling to be abstinent or use highly effective methods of birth control for the
             duration of study participation and for at least 2 weeks after treatment has ended.

          -  Women who are pregnant, nursing, or who plan to become pregnant while in the trial
             Exclusion criterion for Part B Any known contraindication for paclitaxel treatment.
             Not able to tolerate lowest dose of afatinib. Peripheral polyneuropathy &gt;Grade 2
             Further exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hunan Province Tumor Hospital</name>
      <address>
        <city>Changsha</city>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital to Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Hospital Affiliated with Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2015</study_first_submitted>
  <study_first_submitted_qc>November 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2015</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

